Physician profile
John Andrew Roye
NPI 1942200712
$2,799.70
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,000 · 2020: $571 · 2021: $229.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $455.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $403.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $368.91 | 2019-2020 | |
| Edwards Lifesciences Corporation | $294.44 | 2019 | |
| Boston Scientific Corporation | $249.23 | 2019-2020 | |
| Biotronik INC. | $207.94 | 2019-2020 | |
| Pfizer INC. | $177.38 | 2019 | |
| Esperion Therapeutics, INC. | $139.41 | 2020-2021 | |
| Medtronic Vascular, INC. | $122.19 | 2019 | |
| Abbott Laboratories | $104.07 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $103.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $53.42 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $40.35 | 2020 | |
| Arbor Pharmaceuticals, INC. | $24.20 | 2019-2020 | |
| Nuwellis, INC. | $15.67 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.73 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.01 | 2019 | |
| Amarin Pharma, INC. | $12.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.